Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparing Second-Line NABPLAGEM vs. Nab-paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma

NCT06783140 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT06783140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06783140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparing Second-Line NABPLAGEM vs. Nab-paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
University Health Network, Toronto
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
June 10, 2025
Completion date
June 2, 2031
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brca1/2 mutation, palb2 gene mutation, pancreatic cancer, advanced or metastatic